Crossmark

Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan

Crossref DOI link: https://doi.org/10.1007/s12325-022-02411-y

Published Online: 2023-01-24

Published Print: 2023-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ogura, Takashi

Inoue, Yoshikazu https://orcid.org/0000-0003-3994-874X
Azuma, Arata https://orcid.org/0000-0003-0506-9966
Homma, Sakae

Kondoh, Yasuhiro

Tanaka, Katsumi

Ochiai, Kaori

Sugiyama, Yukihiko

Nukiwa, Toshihiro
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02607722 at ClinicalTrials.gov

Documents that mention this clinical trial

Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan
https://doi.org/10.1007/s12325-024-03079-2

Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan
https://doi.org/10.1007/s12325-022-02411-y
Funding

Funding for this research was provided by:

Boehringer Ingelheim
License Information

Text and Data Mining valid from 2023-01-24

Version of Record valid from 2023-01-24
More Information

Article History

Received: 18 October 2022

Accepted: 14 December 2022

First Online: 24 January 2023

Document is current

Any future updates will be listed below